Samsung Biologics revenue up 18.5%, FY26 growth guidance raised to 20%
Samsung Biologics reported third-quarter revenue up 18.5% year on year and raised its FY26 growth guidance to 20%, while net profit declined, per TradingView.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
Samsung Biologics posted third-quarter revenue growth of 18.5% year on year, according to TradingView. Net profit declined over the same period, and the EBITDA margin narrowed.
The company raised its revenue growth guidance for fiscal 2026 to 20%. Higher facility utilization and the stabilization of the Rockville site were cited as the main drivers of growth.
why it matters
The gap between revenue and profit is the key point for the market: sales growth alongside lower net profit points to pressure on costs or margins. The higher forecast signals confidence in demand for contract biologics manufacturing, but investors will watch margin trends in upcoming reports closely.
market impact
Samsung Biologics and the CDMO sector: the higher revenue forecast supports interest, while weaker profit tempers it
tags
instruments
sources
- Samsung Biologics : Revenue grew 18.5% as FY26 growth guidance rose to 20% — TradingView, 21 October 2026 at 19:52 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗